Meeting
2014 ASCO Annual Meeting
Improved disease-free survival with intraportal chemotherapy plus adjuvant chemotherapy (mFOLFOX6) as adjuvant treatment in colon cancer.
Authors
Wenju Chang
Fudan University, Shanghai, China
Wenju Chang , Jianmin Xu , Ye Wei , Li Ren , Tianshu Liu , Jingwen Chen , Dexiang Zhu , Qi Lin , Xinyu Qin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01972503
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3616)
DOI
10.1200/jco.2014.32.15_suppl.3616
Abstract #
3616
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Survival of stage III colon cancer patients with adjuvant chemotherapy: Experience from a specialized cancer institute in Latinoamerica-Peru.
First Author: Eder Christian Veramendi Cabana
Poster
2020 ASCO Virtual Scientific Program
Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
First Author: Zehua Wu
Poster
2020 Gastrointestinal Cancers Symposium
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis.
First Author: Suganija Lakkunarajah
Poster
2019 Gastrointestinal Cancers Symposium
Outcomes and utilization of adjuvant chemotherapy (AT) for stage II colon cancer (CC-II) in elderly population.
First Author: Afsaneh Barzi